0001209191-20-038339.txt : 20200622 0001209191-20-038339.hdr.sgml : 20200622 20200622211756 ACCESSION NUMBER: 0001209191-20-038339 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200622 FILED AS OF DATE: 20200622 DATE AS OF CHANGE: 20200622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Howton David T CENTRAL INDEX KEY: 0001529297 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 20980146 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-22 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001529297 Howton David T 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 0 1 0 0 EVP, General Counsel Common Stock 2020-06-22 4 M 0 1280 13.71 A 33151 D Common Stock 2020-06-22 4 M 0 1858 13.71 A 35009 D Common Stock 2020-06-22 4 M 0 56984 23.85 A 91993 D Common Stock 2020-06-22 4 M 0 45000 29.03 A 136993 D Common Stock 2020-06-22 4 S 0 6009 168.61 D 130984 D Common Stock 2020-06-22 4 S 0 8086 169.56 D 122898 D Common Stock 2020-06-22 4 S 0 35757 170.59 D 87141 D Common Stock 2020-06-22 4 S 0 55270 171.50 D 31871 D Stock option (right to buy) 13.71 2020-06-22 4 M 0 1280 0.00 D 2017-02-28 2026-02-28 Common Stock 1280 0 D Stock option (right to buy) 13.71 2020-06-22 4 M 0 1858 0.00 D 2017-02-28 2026-02-28 Common Stock 1858 0 D Stock option (right to buy) 23.85 2020-06-22 4 M 0 56984 0.00 D 2013-11-05 2022-11-05 Common Stock 56984 0 D Stock option (right to buy) 29.03 2020-06-22 4 M 0 45000 0.00 D 2015-02-28 2024-02-28 Common Stock 45000 7708 D This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. /s/ David Tyronne Howton 2020-06-22